Last reviewed · How we verify

NCT06628076

Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated from Patients with Hospital Acquired Infections in Sohag University Hospitals, Egypt

Not yet recruiting Last updated 4 October 2024
What this trial tests

trial testing Culture specific antibiotic therapy in Infections, Nosocomial in 150 participants. Not yet recruiting.

Timeline
10 October 2024
Primary endpoint
10 October 2024
30 December 2025

Quick facts

Lead sponsorSohag University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment150
Start date10 October 2024
Primary completion10 October 2024
Estimated completion30 December 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

Under 90, any sex, with Infections, Nosocomial or Infections, Respiratory Tract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06628076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing